PL2021078T3 - Siarczanowany kwas hialuronowy do leczenia degeneracyjnej choroby zwyrodnieniowej stawów - Google Patents

Siarczanowany kwas hialuronowy do leczenia degeneracyjnej choroby zwyrodnieniowej stawów

Info

Publication number
PL2021078T3
PL2021078T3 PL07724845T PL07724845T PL2021078T3 PL 2021078 T3 PL2021078 T3 PL 2021078T3 PL 07724845 T PL07724845 T PL 07724845T PL 07724845 T PL07724845 T PL 07724845T PL 2021078 T3 PL2021078 T3 PL 2021078T3
Authority
PL
Poland
Prior art keywords
hyaluronic acid
treating degenerative
degenerative osteoarthritis
sulphated hyaluronic
sulphated
Prior art date
Application number
PL07724845T
Other languages
English (en)
Inventor
Lanfranco Callegaro
Davide Renier
Original Assignee
Fidia Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fidia Farm Spa filed Critical Fidia Farm Spa
Publication of PL2021078T3 publication Critical patent/PL2021078T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/014—Hydrolysed proteins; Derivatives thereof from animals from connective tissue peptides, e.g. gelatin, collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
PL07724845T 2006-05-31 2007-05-03 Siarczanowany kwas hialuronowy do leczenia degeneracyjnej choroby zwyrodnieniowej stawów PL2021078T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT000219A ITPD20060219A1 (it) 2006-05-31 2006-05-31 Composizioni farmaceutiche contenenti acido ialuronico solfatato nel trattamento dell'osteoartrosi
EP07724845.8A EP2021078B1 (en) 2006-05-31 2007-05-03 Sulphated hyaluronic acid for treating degenerative osteoarthritis
PCT/EP2007/003920 WO2007137674A1 (en) 2006-05-31 2007-05-03 Sulphated hyaluronic acid for treating degenerative osteoarthritis

Publications (1)

Publication Number Publication Date
PL2021078T3 true PL2021078T3 (pl) 2015-08-31

Family

ID=38353080

Family Applications (2)

Application Number Title Priority Date Filing Date
PL14173163T PL2786782T3 (pl) 2006-05-31 2007-05-03 Siarczanowany kwas hialuronowy do leczenia degeneracyjnej choroby zwyrodnieniowej stawów
PL07724845T PL2021078T3 (pl) 2006-05-31 2007-05-03 Siarczanowany kwas hialuronowy do leczenia degeneracyjnej choroby zwyrodnieniowej stawów

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL14173163T PL2786782T3 (pl) 2006-05-31 2007-05-03 Siarczanowany kwas hialuronowy do leczenia degeneracyjnej choroby zwyrodnieniowej stawów

Country Status (14)

Country Link
US (3) US20090197807A1 (pl)
EP (2) EP2021078B1 (pl)
JP (1) JP5537933B2 (pl)
KR (1) KR20090014359A (pl)
CN (1) CN101454048B (pl)
AU (1) AU2007268195A1 (pl)
CA (1) CA2653660C (pl)
DK (1) DK2021078T3 (pl)
ES (2) ES2619309T3 (pl)
IT (1) ITPD20060219A1 (pl)
MX (1) MX2008015212A (pl)
PL (2) PL2786782T3 (pl)
SI (2) SI2786782T1 (pl)
WO (1) WO2007137674A1 (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5088864B2 (ja) * 2007-03-16 2012-12-05 オリンパス株式会社 生体組織補填材とその製造方法
US20100285134A1 (en) * 2008-02-15 2010-11-11 Bone Therepeutics Pharmaceutical composition for use in the treatment and/or the prevention of osteoarticular diseases
US8343942B2 (en) 2008-04-04 2013-01-01 University Of Utah Research Foundation Methods for treating interstitial cystitis
JP5758797B2 (ja) * 2008-04-04 2015-08-05 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション アルキル化半合成グリコサミノグリカンエーテルならびにその製造および使用方法
IT1393945B1 (it) 2009-04-21 2012-05-17 Fidia Farmaceutici Composizioni comprendenti acido ialuronico, acido ialuronico solfatato, calcio e vitamina d3 nel trattamento delle malattie osteoarticolari e muscoloscheletriche
IT1396003B1 (it) * 2009-05-14 2012-11-09 Fidia Farmaceutici Ialuronidasi extracellulare da streptomyces koganeiensis
IT1397247B1 (it) * 2009-05-14 2013-01-04 Fidia Farmaceutici Nuovi agenti regolatori dell'attivita' citochinica
IT1397246B1 (it) * 2009-05-14 2013-01-04 Fidia Farmaceutici Nuovi medicamenti ad uso topico a base di acido ialuronico solfatato come agente attivante o inibente l'attivita' citochinica
IT1397522B1 (it) * 2009-12-21 2013-01-16 Solartium Entpr Ltd Uso di una combinazione per il trattamento dell'osteoartrosi
EP2384759A1 (en) * 2010-05-06 2011-11-09 Suomen Punainen Risti Veripalvelu Sulphated hyaluronic acid in combination with G-CSF for use in mobilising blood stem cells
US8546353B2 (en) 2010-05-06 2013-10-01 Glykos Finland Oy Compounds and combinations
CA2830933A1 (en) 2011-03-23 2012-09-27 University Of Utah Research Foundation Methods for treating or preventing urological inflammation
CN103796659A (zh) * 2011-07-13 2014-05-14 车比奥及戴奥斯泰有限公司 包含胶原、透明质酸衍生物和哺乳动物脐带来源干细胞的软骨细胞治疗物
TWI466675B (zh) * 2011-09-16 2015-01-01 Univ China Medical 用於抑制發炎之醫藥組合物
ITPD20120098A1 (it) * 2012-03-30 2013-10-01 Fidia Farmaceutici "nuove formulazioni faramaceutiche contenenti condroitin solfato e derivati dell'acido ialuronico"
EP2897974B1 (en) 2012-09-20 2018-03-28 Mackay Memorial Hospital Use of pedf-derived polypeptides for treating osteoarthritis
US20140186306A1 (en) * 2012-09-28 2014-07-03 Paul Ronald Plante Novel ampk agonist compositions and methods of use
WO2014165513A2 (en) * 2013-04-02 2014-10-09 The Regents Of The University Of California Ethylsulfonated hyaluronic acid biopolymers and methods of use thereof
KR101895950B1 (ko) * 2015-12-18 2018-09-06 (주)한국비엠아이 골관절염 치료를 위한 친수화된 설파살라진 및 히알루론산을 포함하는 조성물 및 이의제조방법
EP3423920B1 (en) 2016-03-02 2022-02-09 Bortek Bor Teknolojileri Ve Mekatronik Sanayi Ticaret Anonim Sirketi Therapeutic mixtures for treating osteoarthritis comprising nano hexagonal boron nitride composition
TWI632915B (zh) * 2016-05-31 2018-08-21 大江生醫股份有限公司 用以治療關節炎之醫藥組成物
WO2018053111A1 (en) 2016-09-15 2018-03-22 University Of Utah Research Foundation In situ gelling compositions for the treatment or prevention of inflammation and tissue damage
KR102248721B1 (ko) * 2018-09-13 2021-05-07 주식회사 엘지화학 황산화 히알루론산 기반의 하이드로겔 및 이를 포함하는 약제학적 조성물
CN111228653A (zh) 2018-11-13 2020-06-05 格莱科米拉治疗公司 用电离辐射加强癌症治疗的方法
WO2021133000A1 (ko) * 2019-12-23 2021-07-01 주식회사 엘지화학 항염 또는 항혈관신생용 약제학적 조성물

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH666897A5 (fr) 1983-10-11 1988-08-31 Fidia Spa Fractions d'acide hyaluronique non inflammatoire, procedes et compositions pharmaceutiques.
US4713448A (en) 1985-03-12 1987-12-15 Biomatrix, Inc. Chemically modified hyaluronic acid preparation and method of recovery thereof from animal tissues
ITPD940054A1 (it) * 1994-03-23 1995-09-23 Fidia Advanced Biopolymers Srl Polisaccaridi solfatati
DE69621528T2 (de) 1995-02-07 2003-01-16 Shiseido Co. Ltd., Tokio/Tokyo Anti-inflamatorische agenzien
ATE229038T1 (de) * 1997-04-04 2002-12-15 Fidia Advanced Biopolymers Srl N-sulfatierte hyaluronsäureverbindungen, ihre derivate und verfahren zu ihrer herstellung
IT1294797B1 (it) * 1997-07-28 1999-04-15 Fidia Advanced Biopolymers Srl Uso dei derivati dell'acido ialuronico nella preparazione di biomateriali aventi attivita' emostatica fisica e tamponante
US6645948B2 (en) 1998-03-24 2003-11-11 George D. Petito Nutritional composition for the treatment of connective tissue
US6476005B1 (en) 1998-03-24 2002-11-05 George D. Petito Oral and injectable nutritional composition
IT1302534B1 (it) * 1998-12-21 2000-09-05 Fidia Advanced Biopolymers Srl Composizioni iniettabili, biocompatibili e biodegradabili comprendentialmeno un derivato dell'acido ialuronico, cellule condrogeniche, per
IT1306644B1 (it) 1999-04-08 2001-10-02 Fidia Advanced Biopolymers Srl Strutture tridimensionali comprendenti derivati dell'acido ialuronicoottenibili mediante la tecnica antisolvente supercritico.
US6288043B1 (en) * 1999-06-18 2001-09-11 Orquest, Inc. Injectable hyaluronate-sulfated polysaccharide conjugates
JP2001163789A (ja) * 1999-12-13 2001-06-19 Maruho Co Ltd マトリックスメタロプロテアーゼ阻害用医薬組成物
US6924273B2 (en) 2000-10-03 2005-08-02 Scott W. Pierce Chondroprotective/restorative compositions and methods of use thereof
DE10053053A1 (de) * 2000-10-19 2002-05-16 Knoell Hans Forschung Ev Pharmazeutische Formulierungen zur Hemmung von entzündlichen Arthritiden
US6607745B2 (en) 2001-05-18 2003-08-19 Harry Leneau Ingestion of hyaluronic acid for improved joint function and health
MXPA01011542A (es) 2001-11-13 2003-05-22 Alcon Inc Regeneracion del cartilago articular da°ado por la osteoartritis de grado i y ii, mediante la aplicacion intra-articular de una mezcla de hialuronato de sodio y de condroitin sulfato en un vehiculo de gel.
US20060094643A1 (en) * 2002-07-03 2006-05-04 Yuri Svirkin Compositions of hyaluronic acid and methods of use
CZ13928U1 (cs) 2003-10-08 2004-01-20 Cpn Spol. S R.O. Dietetický přípravek pro prevenci a léčbu osteoporózy
ITPD20040053A1 (it) * 2004-02-27 2004-05-27 Fidia Advanced Biopolymers Srl Biomateriali costituiti da derivati dell'acido ialuronico come nuova terapia di cura per la protezione e la la riparazione della cartilagine articolare danneggiata per osteoartrosi

Also Published As

Publication number Publication date
AU2007268195A1 (en) 2007-12-06
MX2008015212A (es) 2008-12-09
CN101454048A (zh) 2009-06-10
EP2786782B1 (en) 2017-03-08
DK2021078T3 (en) 2015-04-27
HK1123235A1 (en) 2009-06-12
ES2619309T3 (es) 2017-06-26
EP2786782A1 (en) 2014-10-08
JP2009538840A (ja) 2009-11-12
US20140221294A1 (en) 2014-08-07
EP2021078A1 (en) 2009-02-11
EP2021078B1 (en) 2015-02-25
SI2786782T1 (sl) 2017-06-30
US20120165254A1 (en) 2012-06-28
US9295690B2 (en) 2016-03-29
CA2653660C (en) 2014-07-29
ITPD20060219A1 (it) 2007-12-01
KR20090014359A (ko) 2009-02-10
CA2653660A1 (en) 2007-12-06
HK1197040A1 (en) 2015-01-02
SI2021078T1 (sl) 2015-05-29
JP5537933B2 (ja) 2014-07-02
PL2786782T3 (pl) 2017-08-31
ES2534763T3 (es) 2015-04-28
US8765714B2 (en) 2014-07-01
US20090197807A1 (en) 2009-08-06
CN101454048B (zh) 2013-06-19
WO2007137674A1 (en) 2007-12-06

Similar Documents

Publication Publication Date Title
SI2786782T1 (sl) Sulfatirana hialuronska kislina za zdravljenje degenerativnega osteoartritisa
EP1991365B8 (en) Methods for forming silver-nanoparticle treated surfaces
EP2231230A4 (en) ARTICULAR INJECTION SYSTEM
PL3498262T3 (pl) Kwas hialuronowy - żel do wstrzykiwania
ZA201101055B (en) Compositions and methods for treating osteoarthritis
PL2343983T3 (pl) Sposób obróbki materiałów biologicznych
ZA200903919B (en) Hyaluronic acid gel for intradermal injection
ZA200908898B (en) Dentifruce compositions for treating xerostomia
EP2123631A4 (en) PROCESS FOR PRODUCTION OF -ALCOXYPROPIONAMIDE
PL2129763T3 (pl) Środek do obróbki twardych powierzchni
EP2117620A4 (en) PROTOELASTINE BIOMATERIALS FROM TROOELASTINE
PL2129760T3 (pl) Produkt do traktowania twardych powierzchni
PL2445510T3 (pl) Kompozycja do leczenia zwyrodnieniowych chorób stawów
GB0602125D0 (en) Sensitizer-incorporated biomaterials
GB0611210D0 (en) Process
GB0614823D0 (en) Process
SI2376121T2 (sl) Zdravljenje osteoartritisa
EP2322220A4 (en) THERAPEUTIC AGENT OR PREVENTIVE AGENT FOR ARTHROSIS
GB0600914D0 (en) Process
GB0607395D0 (en) Process
PL2252302T3 (pl) Kompozycja do leczenia zapalenia kości i stawów
GB0604874D0 (en) Process
GB0611741D0 (en) Process
GB0614485D0 (en) Process
IL201307A0 (en) Ibandronate process